---
title: "Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology | VVY Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280866041.md"
description: "Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology | VVY Stock News"
datetime: "2026-03-27T22:01:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280866041.md)
  - [en](https://longbridge.com/en/news/280866041.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280866041.md)
generator: "portal-rs"
---

# Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology | VVY Stock News

Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology | VVY Stock News

### Related Stocks

- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [VVOS.US](https://longbridge.com/en/quote/VVOS.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)

## Related News & Research

- [Vivos Therapeutics partners with South Palm Cardiovascular to launch Florida sleep testing, treatment center](https://longbridge.com/en/news/297327635.md)
- [Vivos Therapeutics opens Henderson, Nevada sleep testing and treatment center, targets over $10 million annual capacity](https://longbridge.com/en/news/296505979.md)
- [Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript](https://longbridge.com/en/news/295983640.md)
- [Vivos Therapeutics issues new US patent broadening protection for Vivos CARE devices](https://longbridge.com/en/news/295581752.md)
- [Why Webuy Global Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket](https://longbridge.com/en/news/297493471.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**